Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Uptravi

Selexipag

RLDNDA 207947 8 strengths Actelion
Approved
Dec 21, 2015
Strengths
8
Listed patents
12
Applications
2

What does the FDA Orange Book show for Uptravi?

Uptravi contains Selexipag and appears in 2 FDA Orange Book applications. NDA 207947 is the lead filing, with 8 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
2; lead NDA 207947

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
Actelion Pharmaceuticals US Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
8

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
AB

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
12

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0010.2MGTABLETORALPrescriptionAB
RLD
0020.4MGTABLETORALPrescriptionAB
RLDRS
0030.6MGTABLETORALPrescriptionAB
RLD
0040.8MGTABLETORALPrescriptionAB
RLD
0051MGTABLETORALPrescriptionAB
RLD
0061.2MGTABLETORALPrescriptionAB
RLD
0071.4MGTABLETORALPrescriptionAB
RLD
0081.6MGTABLETORALPrescriptionAB
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Actelion Pharmaceuticals US Inc

The Orange Book identifies this organization as the applicant responsible for NDA 207947.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

8 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AB across rated presentations

An AB code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.

Patent & exclusivity record

12 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jun 01, 2037. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

3 other ANDAs and 0 other NDAs found

2 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 207947 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-207947

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

8 approved presentations · NDA 207947
TE ABRLD
Strength
0.2MG
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    10 yr 9 mo ago

  2. Today

  3. Patent 7205302 expires

    Listed drug substance patent expiration.

    in 3 mo

  4. Patent 7205302*PED expires

    Listed listed patent expiration.

    in 9 mo

  5. Patent 9173881 expires

    Listed method-of-use patent (U-1798) expiration.

    in 3 yr 1 mo

  6. Patent 9173881*PED expires

    Listed listed patent expiration.

    in 3 yr 7 mo

  7. Patent 9284280 expires

    Listed method-of-use patent (U-1831) expiration.

    in 4 yr

  8. Patent 8791122 expires

    Listed drug substance patent expiration.

    in 4 yr 1 mo

  9. Patent 9284280*PED expires

    Listed listed patent expiration.

    in 4 yr 6 mo

  10. Patent 8791122*PED expires

    Listed listed patent expiration.

    in 4 yr 7 mo

  11. Patent 10821108 expires

    Listed drug product patent expiration.

    in 10 yr 6 mo

  12. Patent 10828298 expires

    Listed drug product patent expiration.

    in 10 yr 6 mo

  13. Patent 10821108*PED expires

    Listed listed patent expiration.

    in 11 yr

  14. Patent 10828298*PED expires

    Listed listed patent expiration.

    in 11 yr

Patent & exclusivity timeline

Protection horizon
2026202820302032203420362038TodayPatent 7205302: 2026-10-31Patent 7205302Patent 7205302*PED: 2027-04-30Patent 7205302*PEDPatent 9173881: 2029-08-12Patent 9173881Patent 9173881*PED: 2030-02-12Patent 9173881*PEDPatent 9284280: 2030-06-25Patent 9284280Patent 8791122: 2030-08-01Patent 8791122Patent 9284280*PED: 2030-12-25Patent 9284280*PEDPatent 8791122*PED: 2031-02-01Patent 8791122*PEDPatent 10821108: 2036-12-01Patent 10821108Patent 10828298: 2036-12-01Patent 10828298Patent 10821108*PED: 2037-06-01Patent 10821108*PEDPatent 10828298*PED: 2037-06-01Patent 10828298*PED
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

SELEXIPAG

Strength

0.2MG

Dosage form

TABLET

Route

ORAL

TE code

AB

Application

NDA 207947

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7205302in 3 mo
SubstanceProductU-1797
7205302*PEDin 9 mo
9173881in 3 yr 1 mo
U-1798
9173881*PEDin 3 yr 7 mo
9284280in 4 yr
U-1831
8791122in 4 yr 1 mo
SubstanceProduct
9284280*PEDin 4 yr 6 mo
8791122*PEDin 4 yr 7 mo
10821108in 10 yr 6 mo
ProductU-2992
10828298in 10 yr 6 mo
ProductU-2991
10821108*PEDin 11 yr
10828298*PEDin 11 yr

Other FDA applications for Uptravi

1 additional filing

The FDA has approved 2 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Uptravi, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
NDA 214275ActelionJul 29, 20211—Prescription

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Selexipag family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Uptravi: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 207947 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo